Xilio Therapeutics (XLO) Cash from Financing Activities (2020 - 2026)

Xilio Therapeutics has reported Cash from Financing Activities for 7 years, with the latest figure at $35.7 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 638.97% year-over-year to $35.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $118.6 million (up 258.74% YoY) and the FY2025 annual result came in at $87.8 million, up 200.64% from the prior year.
• Cash from Financing Activities steadied at $35.7 million in Q1 2026 per XLO's latest filing, from $35.9 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $47.4 million in Q2 2025 and troughed at -$2.2 million in Q3 2023.
• A 5-year average of $8.6 million and a median of -$5000.0 in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities slumped 33660.0% in 2023, then soared 2120.46% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$21000.0 in 2022, then slumped by 7680.95% to -$1.6 million in 2023, then soared by 601.96% to $8.2 million in 2024, then surged by 337.28% to $35.9 million in 2025, then dropped by 0.44% to $35.7 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $35.7 million, $35.9 million, and -$285000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.